A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
Advances in therapy|2023|Sandhu H et al.|16 citations
OBJECTIVES: The objective of the current preliminary study was to present the cost-effectiveness analyses submitted to the National Institute for Health and Care Excellence (NICE) (TA10765) that deemed semaglutide 2.4 mg subcutaneous (s.c.) injection…
PMID: 36630047
Medicine|2023|Mawardi H et al.|3 citations
RATIONALE: Obesity and diabetes of different types are considered global health risks with rising prevalence. In addition to low-calorie diet and daily exercise, several treatment options have been introduced to help patient in needs. Semaglutide (Oz…
PMID: 38206684
JAMA|2023|Suran M|43 citations
PMID: 37099334
Obesity (Silver Spring, Md.)|2023|Kelly A et al.|33 citations
OBJECTIVE: The aim of this study was to examine how improvement in BMI with the glucagon-like peptide-1 receptor agonist semaglutide translated to changes in BMI category in a post hoc analysis of the double-blind, phase 3a randomized controlled Sema…
Randomized Controlled Trial
PMID: 37196421
Journal of cardiovascular development and disease|2023|Yamada H et al.|20 citations
Glucagon-like peptide-1 receptor agonists (GLP-1RA) have a more potent glycated hemoglobin (HbA1c)-lowering effect than existing therapies and are widely used for treating type 2 diabetes mellitus (T2DM). Once-daily oral semaglutide is the world's fi…
PMID: 37103055
Journal of medical economics|2023|Berry S et al.|2 citations
AIMS: In the SUSTAIN 6 cardiovascular outcomes trial, once-weekly semaglutide was associated with a statistically significant reduction in major adverse cardiovascular events compared with placebo. To date, no studies have assessed how accurately exi…
PMID: 37525970
MMW Fortschritte der Medizin|2023|Overbeck P
PMID: 37828312
Physiological reports|2023|Feng J, Shao W, Jin T|11 citations
Metabolic functions of GLP-1 and its analogues have been extensively investigated. In addition to acting as an incretin and reducing body weight, we and others have suggested the existence of GLP-1/fibroblast growth factor 21 (FGF21) axis in which li…
Animal Study
PMID: 36905134
Science (New York, N.Y.)|2023|Leslie M|7 citations
Clinical trials will gauge whether GLP-1 analogs curb drug and alcohol cravings.
PMID: 37651529
Diabetes, obesity & metabolism|2023|Jiang P et al.|3 citations
AIM: To develop and investigate an imbalanced dual gastric inhibitory polypeptide receptor (GIPR)/glucagon-like peptide-1 receptor (GLP-1 R) agonist with Fc fusion protein structure. METHODS: We designed and constructed an Fc fusion protein that is a…
Animal Study
PMID: 37580307
Journal of the American Heart Association|2023|Unknown authors|1 citation
PMID: 36892066
Pharmaceuticals (Basel, Switzerland)|2023|Hachuła M et al.|4 citations
Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) is associated with the excessive collection of lipids in hepatocytes. Over 75% of diabetes patients typically have MASLD, and, at the same time, the presence of MASLD increases the risk…
PMID: 37764998
Expert review of clinical pharmacology|2023|Tsiampali C et al.|6 citations
INTRODUCTION: Nonalcoholic fatty liver disease (NAFLD) is a highly prevalent disease, associated with obesity, type 2 diabetes mellitus and dyslipidemia, which can lead to liver cirrhosis and hepatocellular carcinoma in some patients. Apart from life…
Review
PMID: 37864548
The Annals of pharmacotherapy|2023|Bradley C et al.|12 citations
OBJECTIVE: The objective of this article was to review pharmacology, efficacy, safety, and place in therapy of tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. DATA SOURCES:…
Review
PMID: 36367094
Obesity (Silver Spring, Md.)|2023|Powell W et al.|22 citations
OBJECTIVE: Approved by the Food and Drug Administration (FDA) in 2017 for diabetes and in 2021 for weight loss, semaglutide has seen widespread use among individuals who aim to lose weight. The aim of this study was to evaluate weight loss and the in…
PMID: 37593896
Nutrients|2023|Hayashi D et al.|33 citations
As GLP-1 receptor agonists, like semaglutide, emerge as effective treatments for weight management, anecdotal reports from patients and clinicians alike point to a reduction in what has been colloquially termed "food noise", as patients report experi…
Review
PMID: 38004203
The Annals of pharmacotherapy|2023|Meyer J et al.|2 citations
BACKGROUND: Escalating doses of insulin required with progression of type 2 diabetes may lead to weight gain. Weight loss associated with semaglutide may be beneficial. However, data on the use of semaglutide in patients requiring high daily doses of…
PMID: 35778801
Frontiers in endocrinology|2023|Xie Z et al.|33 citations
PURPOSE: This study aimed to perform a network meta-analysis to objectively evaluate the efficacy and safety of 10 Glucagon-like peptide-1 receptor agonists (GLP-1RAs) in combination with metformin that is approved for use worldwide in patients with…
Review
PMID: 37701904
World journal of gastroenterology|2023|Zhu K et al.|27 citations
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease. The prevalence and disease burden of NAFLD are projected to exponentially increase resulting in significant healthcare expenditures and lower health-…
Meta-Analysis
PMID: 37899788
Einstein (Sao Paulo, Brazil)|2023|Queiroz V et al.|13 citations
Pulmonary aspiration of gastric residues during anesthesia is a potentially fatal complication for which no specific treatment is available. The primary way to prevent its occurrence in the context of elective surgeries is adherence to fasting protoc…
Case Report
PMID: 38126547